Clinical Trials Directory

Trials / Unknown

UnknownNCT06459622

Predictive Factors in Chronic Rhinosinusitis With Nasal Polyps

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
102 (estimated)
Sponsor
Katrina Atef Habashy · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

The study will be conducted to identify factors predicting the response of chronic rhinosinusitis with nasal polyps ( CRSwNP) to oral corticosteroids.

Detailed description

Treatment of nasal polyposis is divided into medical or surgical treatment . Steroids are widely used as the most effective medicine in nasal polyposis. Although oral corticosteroids are one of the frequently used treatments in the management of chronic rhinosinusitis with nasal polyps (CRSwNP), there is lack of effective means of predicting corticosteroid sensitivity in those patients. It was reported that the overall sensitivity rates of corticosteroid therapy to nasal polyps( NP) were only between 53.8% and 80%.. Many reports stated that serum and tissue interleukeine 25 (IL 25) and serum and tissue eosinophalia are good predictors to the response of CRSwNP to oral corticosteroids. Interleukeine 25(IL-25), an important epithelial-derived proinflammatory cytokine, plays various roles in different inflammatory and allergic diseases, such as asthma and atopic dermatitis . Hong et al demonstrated that the levels of IL-25 in NP tissues and in serum, as well as the NP endoscopic scores, were significantly elevated in the corticosteroid-sensitive patients compared with the non-sensitive ones. In general, eosinophilic NPs are pharmacologically glucocorticoid responsive, but non-eosinophilic or neutrophilic CRSwNP is frequently resistant to steroid treatment.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTSerum IL_25 and eosinophils in nasal polyp tisueeSerum IL-25 and eosinophils in nasal polyps tisuer obtained and measured to identify the sensitivity of nasal polyps to corticosteroids

Timeline

Start date
2024-07-01
Primary completion
2025-03-01
Completion
2025-05-01
First posted
2024-06-14
Last updated
2024-06-14

Source: ClinicalTrials.gov record NCT06459622. Inclusion in this directory is not an endorsement.